Bowling Portfolio Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Bowling Portfolio Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,898	Closed	-$399K	–	411
2019 Q1	$399K	Sell	7,898 -32	-0.4%	-$1.42K	0.06%	311
2018 Q4	$319K	Buy	+7,930	New	+$409K	0.06%	316
2018 Q2	–	Sell	-31,666	Closed	-$1.67M	–	413
2018 Q1	$1.67M	Sell	31,666 -2,143	-6%	-$125K	0.23%	171
2017 Q4	$1.81M	Buy	+33,809	New	+$1.88M	0.24%	144

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bowling Portfolio Management's EGRX Position: Q2 2019 in Review

Bowling Portfolio Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2019, closing a stake of 7,898 shares — an estimated $399K sold.

Bowling Portfolio Management first reported a position in EGRX in Q4 2017 and held it in 4 quarters. The position peaked at $1.81M in Q4 2017. 180 funds tracked by Wall St. Rank hold EGRX as of Q2 2019.

Bowling Portfolio Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Bowling Portfolio Management sold 7,898 Eagle Pharmaceuticals, Inc. shares in Q2 2019, an estimated $399K.
Bowling Portfolio Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Bowling Portfolio Management's Eagle Pharmaceuticals, Inc. position peaked at $1.81M in Q4 2017.
180 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2019.

Based on Bowling Portfolio Management's 13F filing for Q2 2019, filed 25 Jul 2019.